Skip to main content

Table 1 Baseline demographics and patients’ characteristics of all patients and of subgroups according to disease outcome (all data collected at baseline)

From: Serum KL-6 is a predictor of outcome in pulmonary alveolar proteinosis

  

Outcome

All patients

Remission

Progression

p

N=33

N=17 (51) *

N=16 (49)

Gender (M/F) N(%)

18/15 (54/46)

6/11

12/4

0.016†

Age (yrs)

49±12 (19–79)

50±9

47±15

n.s.

Smoking habits (never/ex/current) N(%)

5/12/16 (15/36/49)

5/5/7

0/7/9

0.055†

BMI (kg/m2)

26±5 (19–36)

28±4

25±5

n.s.

PaO2 (mmHg)

72±15 (47–117)

78±13

63±12

0.002

A-aDO2 (mmHg)

37±14 (11–63)

31±11

44±14

0.005

VC (% pred)

80±16 (44–123)

88±13

69±13

0.001

FEV1 (% pred)

75±16 (43–104)

80±15

67±13

0.014

TLC (% pred)

79±17 (42–116)

85±16

70±14

0.009

DLCO (% pred)

57±19 (21–96)

66±12

42±13

0.001

GM-CSF autoantibody (μg/mL) §

48±22

60±17

44±13

0.55

KL-6 (U/mL)

2049±1893

1084±585

3334±2267

0.001

LDH (IU/L) §

283±93 (140–522)

243±69

338±103

0.005

CEA (ng/mL) §

8.5±7 (1–27)

6±4.5

12±5.5

0.048

  1. Unless otherwise indicated, values are expressed as mean ± SD (range).
  2. n.s.= not significant.
  3. * patients who improved or remained stable and did not receive WLL within 18 months prior to the last evaluation.
  4. § the cut-off of normality for each biomarker is reported in the methods.
  5. † Fisher's exact test, for all other comparisons in the table Student's t-test was used.
Back to article page

Orphanet Journal of Rare Diseases

ISSN: 1750-1172